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One of the most important trends in the treatment of
schizophrenia involves its early diagnosis and inter-
vention. The ultimate goal of research is the preven-
tion of the disorder. A major impediment to the devel-
opment of prevention strategies, however, is that we
do not yet know what the liability for schizophrenia is
before the onset of psychosis. Consequently, early
treatment attempts are focused on the “prodrome,”
which involves the early symptoms of psychosis. In a
companion paper, we recently suggested that preven-
tion work should focus not only on the prodrome, but
also on “schizotaxia,” which is a clinically meaningful
condition that may reflect the vulnerability to schizo-
phrenia in the absence of psychosis. Because schizo-
taxia can be assessed prior to the prodrome, studies of
schizotaxia might lead to more effective prevention
programs. We continue the characterization of schizo-
taxia in this paper by focusing on the etiological roots
of schizotaxia, plus its likely neurodevelopmental
course, clinical expression, and treatment. Finally, the
importance of including neurobiological variables in
the conceptualization and eventual diagnosis of
schizotaxia is reviewed.
n understanding of how schizophrenia devel-
ops is essential for developing treatment strategies aimed
at preventing the disorder.Before such strategies can be
formulated,it will be necessary to identify the liability for
schizophrenia.That is, what is the vulnerability to schiz-
ophrenia before the onset of psychosis? Recently, we
addressed this issue in a companion paper to this one by
describing “schizotaxia,” a clinically meaningful condi-
tion that may reflect liability for schizophrenia.
1 In this
paper, we describe the model of schizotaxia further by
focusing on its etiology and development,and on its clin-
ical, neuropsychological, and biological bases.We begin
with a brief review of the concept,followed by a consid-
eration of its genetic and environmental etiologies, and
its likely neurodevelopmental course. Associated clini-
cal and neuropsychological components of schizotaxia
are then reviewed, followed by an update on our
attempts to use these symptoms to develop treatment
protocols. Finally, prospects for future research center
on the need to incorporate biological function into the
conceptualization and treatment of the syndrome.
Schizotaxia
Paul Meehl introduced the term “schizotaxia”in 1962 to
describe the genetic predisposition to schizophrenia,
2
which he believed resulted in a subtle,neural integrative
defect. He proposed that schizotaxic individuals would
eventually develop either schizotypy or schizophrenia,
depending on environmental circumstances. Although
schizotypy (in the form of schizotypal personality disor-
der) eventually entered the psychiatric nomenclature,
schizotaxia did not. Instead, it became associated with
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nia,but not with a clinically meaningful syndrome.
Now,after more than three decades of research,the accu-
mulated evidence suggests that schizotaxia is, in fact, a
clinically consequential condition and a risk factor or
marker for subsequent psychosis.As such,it encompasses
aspects of both vulnerability and disease. In our refor-
mulation of the concept, differences emerged from
Meehl’s original view.While our use of the term remains
consistent with Meehl’s view of it as the underlying defect
among people genetically predisposed to schizophrenia,it
differs from his theory in at least four significant ways.
First,unlike Meehl,we view the etiology of schizotaxia as
genetic and environmental, instead of only genetic. Sec-
ond,we believe the genetic etiology of schizotaxia is best
explained by a multifactorial, polygenic model, rather
than by a single,major gene (Meehl promulgated his the-
ory before molecular genetic data were available, which
may partly account for this aspect of his theory).Third,we
do not view schizotypy or schizophrenia as the only, or
even the most common, outcomes of schizotaxia, while
Meehl viewed them as the primary end points (even after
a later modification of his views).
3 Fourth,unlike Meehl,
we have begun to identify the components of schizotaxia
and to operationalize the concept. Each of these points
will be considered in the course of the following sections,
starting with a consideration of the origins of the disorder.
The etiology 
of schizophrenic illness
Genetic origins
The familial nature of schizophrenia is well known.
4 In a
review of 40 European studies selected for similarities in
diagnostic and ascertainment procedures, Gottesman
showed the following approximate lifetime risks for
schizophrenia to relatives of schizophrenic patients:par-
ents, 6.0%; siblings, 9.0%; offspring (of one parent with
schizophrenia), 13.0%; and offspring of two schizo-
phrenic parents,46.0%.Risks to second-degree relatives
ranged from 6.0% for half-siblings to 2.0% for uncles
and aunts,while the risk for first cousins,a type of third-
degree relative,was approximately 2.0%.Modern family
studies, using narrower diagnostic criteria than those
employed in earlier European studies, have essentially
confirmed both the pattern of risk in families, and the
approximate rates at which they occur.
5
Familial risk rates, of course, do not necessarily imply
genetic causation.Consistent with genetic hypotheses,how-
ever,higher risk rates among relatives are associated with
greater degrees of biological relatedness to a schizophrenic
patient. Moreover, behavioral genetic designs, including
the use of twin and adoption studies,provide overwhelm-
ing evidence of a large genetic component in most cases.
4,5
For example,adoption studies show that the biological off-
spring of patients with schizophrenia show elevated risks
for schizophrenia, even when they are adopted away at
birth and raised by nonschizophrenic parents.
6Twin studies
also show that concordance rates for schizophrenia are
higher in identical twins (who share 100% of their genes)
than they are in fraternal twins (who share an average of
50% of their genes).Estimates of the heritability of schiz-
ophrenia vary depending on the methods of ascertainment.
Kendler and Diehl
7 reported an average heritability of
around 70% in a series of twin studies,while recent studies
using Diagnostic and Statistical Manual of Mental Disor-
ders, Third Edition (DSM-III), DSM-III-R, or DSM-IV
diagnostic criteria demonstrated heritability estimates
between 80% to 86%.
8-10 It should be stressed that, while
these heritability estimates are quite substantial, they are
influenced by a variety of factors, including the nature of
the sample (eg, its size), the phenotypic criteria used for
diagnosis,the statistical model used,the effect sizes of rel-
evant variables,and environmental factors.
Findings from behavioral genetic studies are of particular
importance to the present discussion because they pro-
vide evidence that schizophrenia genes predispose their
carriers not only to schizophrenia, but also to schizo-
phrenia-like disorders, such as schizoaffective disorder
and schizotypal personality disorder. These conditions
are less severe than schizophrenia, but may be caused
by the same genes,
4 suggesting a spectrum of liability for
schizophrenic illness. Consistent with this view, we pro-
posed that genes involved in conferring liability for schiz-
ophrenia are a major etiological component of schizo-
taxia.
11 Moreover, schizotaxia may be a “truer”
expression of the genes that predispose to schizophrenic
illness than is the diagnostic entity of schizophrenia itself,
because the latter condition may include less (etiologi-
cally) specific effects of psychosis.
1,12
Environmental origins
Despite the overwhelming evidence of a genetic influence
in schizophrenia,it is clear that the presence of genes that
Clinical research
258259
confer liability for schizophrenia is not sufficient to cause
the disorder in most cases. The case for environmental
influence in schizophrenia/schizotaxia incorporates evi-
dence from several sources. First, the same behavioral
genetic studies that show the importance of genetic fac-
tors in schizophrenic illness also underscore the impor-
tance of environmental variables. For example, in family
studies, no degree of biological relatedness, including the
circumstance of having two schizophrenic parents,results in
the development of schizophrenia 100% of the time. As
described above,the liability in that case only approaches
an average of 50%.Similarly,the risk of developing schiz-
ophrenia in a monozygotic (MZ) cotwin (who shares 100%
of the other twin’s genes) whose sibling develops schizo-
phrenia is also about 50%,which is far lower than would be
predicted if genetic influence were the only etiologic factor.
Consistent with such findings, Gottesman and Bertelsen
13
showed that rates of schizophrenia in the offspring of iden-
tical twins who were discordant for schizophrenia were
equal.In all these examples,individuals who possessed the
schizophrenia genotype did not necessarily express the dis-
order. Even the high estimates of heritability described
above must be considered in context.Those studies showed
that about 70% to 85% of the differences between people
who develop schizophrenia and those who do not may be
attributed to genetic factors (in the particular samples that
were studied). They did not mean that the overall influ-
ence of genetic factors is that high.
Environmental influences encompass a variety of dimen-
sions. They may be shared by individuals in the same
household (whether related or not) or unshared (that is,
unique, even for MZ twins), and they may occur at any
point in development, from the moment of conception
through prenatal development, birth, maturation, and
senescence. The differential impact of environmental
variables often varies as a function of the stage of devel-
opment at which they are introduced. Environmental
components include psychosocial,biological,and physical
factors that could cause even MZ twins, with their com-
mon genetic endowments, to experience their worlds
quite differently. For example, they may experience dif-
ferent levels of prenatal and perinatal factors, such as
the adequacy of their blood supplies, their positions in
the womb,and birth complications.Later,they may expe-
rience different home and school environments,and dif-
ferent marital experiences, occupational events, or sur-
roundings.
14,15These differences are probably meaningful,
as nonshared environmental influences account for
almost all of the variance in liability to schizophrenia
attributable to environmental effects in several recent
twin studies.
6,8,16
This discussion thus emphasizes the importance of envi-
ronmental variables in addition to genetic ones.How do
the two types of variables interact to cause schizophre-
nia? There is substantial evidence that, in most cases,
schizophrenia is caused by a multifactorial process con-
sisting of multiple genes that act in combination with
adverse environmental factors.
4,17,18 Although the num-
ber of schizophrenia genes is unknown, there is a broad
consensus that single gene theories of schizophrenia are
not viable,even if such theories allow for multiple single
gene variants.
19-22 The multifactorial model of schizo-
phrenia has some support from segregation analysis stud-
ies,
23,24 and cannot be discounted as a viable model of the
etiology of schizophrenia.
Within the domain of multifactorial models,both additive
genetic and interactive models have been posited.
25 Cer-
tainly, genes and environments always interact, but the
point deserves emphasis because it suggests that envi-
ronmental factors may have differential effects on indi-
viduals with different genotypes.In this view,genetically
mediated factors underlie differences in sensitivity to
environmental factors, and/or from environmentally
mediated genetic effects. The consideration of genetic-
environmental influences may help better understand
the nature of at least some environmental risk factors.
Just as geneticists search the entire genome for all of the
many genes that affect susceptibility to schizophrenia,
so must environmental researchers search the entire
“envirome”for all environmental risk factors that affect
the disorder. Once we understand the sum and interac-
tion of all effects from the genome and from the envir-
ome,we will have solved the puzzle of schizophrenia.
To date, at least two broad features of the envirome are
candidate risk factors for schizophrenia:psychosocial fac-
tors and pregnancy/delivery complications.Evidence from
several adoption studies attest to the importance of psy-
chosocial factors.
5 For example, Wahlberg et al,
26 using
data from the Finnish adoption studies,showed that schiz-
ophrenic thought disorder in young adult offspring of
schizophrenic mothers was more likely when their adop-
tive mothers showed deviant communication patterns.
The influence of pregnancy and delivery complications
occurs earlier in development than does the psychosocial
factor mentioned above.As such, it may have a greater
impact on the development of schizotaxia,and will be dis-
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cussed further. More generally, the study of developmen-
tal abnormalities, like pregnancy and delivery complica-
tions,and their interactions with genetic risk factors,facili-
tates an understanding of precursor states for
schizophrenia.
27 Retrospective studies show, for example,
that a history of labor and delivery complications are more
common in individuals who later develop schizophrenia,
compared with normal controls.
28-31 One of these is
preeclampsia, which results in both fetal hypoxia and a
ninefold increase in the risk for subsequent schizophrenia.
32
In reviewing data from the Philadelphia cohort of the
National Collaborative Perinatal Project (NCPP), Can-
non
33 noted a dose-dependent relationship between risk for
schizophrenia and severity of perinatal hypoxia, and
between the risk for schizophrenia and the number of
hypoxia-related birth complications among children of
schizophrenic parents. Pregnancy and delivery complica-
tions that were not related to hypoxia did not increase the
subsequent risk for schizophrenia among children of schiz-
ophrenic patients.
The importance of specifying which type of obstetric
complication is associated with risk for subsequent schiz-
ophrenia was underscored recently by several
researchers (see,for example,references 34 and 35),who
noted that grouping them together produced a some-
what inconsistent body of literature. Other specific
obstetric risk factors were reported to increase the risk
for schizophrenia include multiparity,maternal bleeding
during pregnancy, winter births, malnutrition, and
extreme prematurity.
36,37 Moreover,viral infections during
pregnancy have been related to a predisposition for adult
schizophrenia.
38Although the literature on the effects of
viruses requires more clarification, there are many
reports of positive relationships between such infections
and the later development of schizophrenia.
31 Interest-
ingly,some viral infections associated with schizophrenia
occurred in the second trimester (see, for example, ref-
erence 39) and may help explain postmortem findings
of brain anomalies related to that stage of development
(see,for example,reference 40).Other studies,however,
suggested that viral infections throughout pregnancy and
the neonatal period elevated the risk for subsequent
schizophrenia.
41
Environmental factors thus appear to act in concert with
genetic factors to produce schizotaxia—the liability for
schizophrenia.At least two conclusions relevant for the
formulation of schizotaxia may be drawn from this dis-
cussion. First, it is clear that both genetic and environ-
mental etiological factors have biological consequences
early in development.For this reason,and because these
consequences cannot be parsed out into their purely
genetic and purely environmental components,we have
reformulated Meehl’s view that schizotaxia represents
only the genetic predisposition to schizophrenia. In our
view, schizotaxia results from a combination of both
genetic and environmental etiologies. Because it may
result from the effects of multiple genes and multiple
environmental factors,it may be a heterogeneous condi-
tion,both clinically and etiologically.
Second, the action of these etiological factors in early
development suggests the likelihood that schizotaxia is a
neurodevelopmental condition.Figure 1 reflects our view
of schizotaxia as the liability for schizophrenia.The top of
the figure illustrates our premise that schizotaxia results
from a combination of genetic and adverse environmen-
tal events. Consistent with the view that schizotaxia is a
Clinical research
Figure 1. Model of the neurodevelopmental course of schizo-
taxia. See text for details.
Reproduced from reference 42: Tsuang MT. Defining alternative
phenotypes for genetic studies: what can we learn from studies
of schizophrenia. Neuropsychiatric Genet. 2000. In press. Copy-
right © 2000, Wiley-Liss, Inc.
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neurodevelopmental disorder,it is likely to involve neu-
robiological abnormalities, as well as clinical and neu-
ropsychological difficulties. The middle of the figure
reflects the premise that later environmental events (eg,
adverse psychosocial events, substance abuse, head
injury) interact with schizotaxia to produce prodromal
symptoms, and then schizophrenia. These events stress
the inability of vulnerable individuals to compensate—
either behaviorally or neurobiologically—to additional
challenges, sources of stress, or, possibly, to continued
maldevelopment of prefrontal areas in the second and
third decades of life. The bottom portion of the figure
shows that psychosis has “toxic”effects of its own,which
result in chronic schizophrenia and, possibly, neurode-
generation.Note that in this model,psychosis is a condi-
tion that is distinct from the predisposition to schizo-
phrenia.As noted above,schizotaxia would thus reflect a
truer expression of schizophrenia genes than would
schizotaxia plus psychosis (ie,schizophrenia).
Clinical features and 
treatment of schizotaxia
In light of the etiological and neurodevelopmental frame-
work discussed above, what does the schizotaxia pheno-
type look like? Comprehensive review of many schizo-
taxic features have already been published (see, for
example,the issue of the Schizophrenia Bulletin edited by
Moldin and Erlenmeyer-Kimling,
43 and also reference 11).
Here we seek to summarize portions of that information
that have been relatively well studied and that will facili-
tate the development of strategies aimed at treating
schizotaxia and (eventually) preventing schizophrenia.
Two dimensions likely to meet these criteria, negative
symptoms and neuropsychological deficits,will be empha-
sized, followed by a summary of our initial attempts to
employ these dimensions to create operational criteria
for a treatment protocol. We will then briefly consider
neurobiological aspects of schizotaxia, in the context of
further understanding and treating the condition.
Negative symptoms
Family, twin, and adoption studies provide firm evidence
that relatives of patients with schizophrenia are at high
risk for schizotypal personality disorder,
44-46 which leads
to the issue of which schizotypal symptoms are most com-
mon. Gunderson et al,
47 for example, showed that such
relatives were at high risk for social isolation, interper-
sonal dysfunction,and impoverished affective experiences.
In that study,mild psychotic-like symptoms,such as recur-
rent illusions and magical thinking,were more common in
relatives who were diagnosed with borderline personal-
ity disorder. Tsuang et al
48 reported that negative symp-
toms (especially flat affect and avolition) were significantly
elevated in the families with schizophrenia,while positive
symptoms were not.In the Roscommon family study,odd
speech,social dysfunction,and negative symptoms strongly
discriminated relatives of schizophrenic patients from con-
trols, while positive symptoms, suspicious behavior, and
avoidant symptoms were less discriminating.
49
Consistent with these studies,psychometric assessments
of schizotypal symptoms among relatives of patients with
schizophrenia show a predominance of negative rather
than positive symptoms (see,for example,reference 50).
In summary, the literature thus far shows that nonpsy-
chotic relatives in families with schizophrenia are more
likely to express negative symptoms than positive symp-
toms, although, as the Roscommon study showed, posi-
tive schizotypal symptoms do occur in this group.
Neuropsychological deficits
Compared with normal control subjects, nonpsychotic
relatives of schizophrenic patients show deficits in a vari-
ety of cognitive domains.
11,51,52 Domains that show the
most consistent deficits include auditory attention,verbal
memory, and executive function (eg, abstraction).
11,52 A
recent examination of first-degree, nonpsychotic rela-
tives who had been evaluated 4 years previously
52,53
showed that their neuropsychological deficits were stable
over time.
54Additional analyses showed significant inter-
correlations among the three functions within the rela-
tives, but not among a group of controls, who mainly
showed significant correlations within different tests of
the same function.
55 The significant correlations among
relatives between attention and verbal memory and
between attention and abstraction differed significantly
from these correlations in the control group.Thus, neu-
ropsychological functions that are putative risk indicators
for schizophrenia co-occur to a greater degree within rel-
atives than they do within controls.The finding that other
neuropsychological functions did not co-occur to a
greater degree within relatives provides further support
for the risk indicator status of attention,verbal memory,
and abstraction.
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cal impairments in relatives of schizophrenic patients
are stable traits caused by the set of genes that also
increases the predisposition to schizophrenia.
53-58 Inter-
estingly, when our sample of relatives was divided into
simplex (ie, one schizophrenic relative) and multiplex
(two schizophrenic relatives) groups,the multiplex sam-
ple performed more poorly in several domains, includ-
ing estimated intelligence, immediate and delayed ver-
bal memory,and immediate visual,nonverbal memory.
59
This finding is particularly consistent with the multifac-
torial model of schizophrenia,
4,17,18 which hypothesizes
that no one gene or environmental factor causes schiz-
ophrenia. Rather, it is the sum of multiple genes and
environmental factors that crosses some threshold value
and leads to the disorder. If this is true, then a graded
genetic predisposition to the disorder must exist, such
that the probability of developing schizophrenia or
another schizophrenia spectrum disorder (or showing
related neuropsychological impairments) increases as
the degree of liability increases. Presumably, multiplex
families harbor more schizophrenia genes than simplex
families.Thus,our finding of greater impairments in rel-
atives in multiplex families is consistent with the pre-
dictions of a multifactorial model.
The emphasis accorded to negative symptoms and neu-
ropsychological deficits may evolve as other components
(eg, psychosocial and neurobiological factors) are inte-
grated into the model. It is significant, however, that in
our samples these core features of schizotaxia (negative
symptoms and neuropsychological impairments) occur
in 20% to 50% of first-degree relatives of patients with
schizophrenia.
52,53 In contrast,less than 10% of adult fam-
ily members of schizophrenic patients will be diagnosed
with schizotypal personality disorder, which means that,
unlike schizotypal personality, schizotaxia appears to be
common among relatives of schizophrenic patients.
Because schizotypal personality should be evident by
adulthood, the finding that many schizotaxic adults are
not schizotypal shows that the former condition does not
always evolve into the latter.Moreover,only about 10%
of first-degree relatives will develop schizophrenia,
4
emphasizing further that schizotaxia may be a relatively
stable condition for many adult relatives of schizophrenic
patients.This point does not obviate the more immediate
challenge of validating schizotaxia as a syndrome, and
distinguishing it clearly from schizotypal personality dis-
order. One way to achieve the latter goal might be to
designate schizotaxia as the syndrome of negative symp-
toms and neuropsychological dysfunction observed
among relatives of schizophrenic patients, and schizo-
typal personality disorder as the schizophrenia-like syn-
drome in which positive symptoms dominate the clinical
picture. Reformulating the diagnoses in this manner
would increase the homogeneity of schizotypal personal-
ity and allow researchers to define schizotaxia in a man-
ner that might further validate its status as a syndrome.
Treatment of schizotaxia
There are at least two reasons to consider treating schizo-
taxia. First, because schizotaxia may be a more specific
expression of schizophrenia genes than is the clinical
diagnosis of schizophrenia, the treatment of schizotaxia
might prevent or attenuate the clinical,social,and patho-
physiological difficulties associated with psychosis.
Second, the treatment of schizotaxia in nonpsychotic
relatives could result in the attenuation of clinically
meaningful symptoms. A variety of psychotherapeutic
approaches might be appropriate for this population,
as might some pharmacological approaches.
11 We pro-
posed this latter course of action in a pilot series of four
relatives with schizotaxia.
60 Since that paper was pub-
lished,we have completed two additional cases.The full
inclusion and exclusion criteria were described in that
report and in the companion article to this paper in Dia-
logues in Clinical Neuroscience.
1The clinical criteria for
schizotaxia included moderate deficits in at least two of
the following three neuropsychological domains: long-
term verbal memory,attention,and executive functions.
Moderate deficits were defined as at least 2 standard
deviations below normal in one neuropsychological
domain,and at least 1 standard deviation below normal
in a second neuropsychological domain;moderate levels
of negative symptoms were defined as 6 or more scores
on the Schedule for the Assessment of Negative Symp-
toms rated 3 or higher.Individuals who met these crite-
ria and who provided informed consent received low
doses of risperidone (0.25-2.0 mg) for 6 weeks. Side
effects were temporary and mainly mild.Five out of six
individuals showed marked improvements in attention,
and mild-to-moderate reductions in negative symptoms.
The sixth subject did not show improvement in either
area.This subject also differed from the other cases in
other ways, as her level of overall cognitive ability was
below normal (estimated IQ=75),raising the possibility
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to utilize them falls below certain levels. Regardless of
why the 6th case did not improve,however,the cognitive
and clinical improvements in 5 out of 6 individuals is
encouraging. We stress that these results are prelimi-
nary,and do not advocate the use of this treatment clin-
ically,until larger,better-controlled trials determine the
reliability and validity of our findings.
Current challenges
What must be accomplished to further the study of
schizotaxia and facilitate the development of prevention
strategies for schizophrenia? Perhaps most importantly,
schizotaxia needs to be validated as a syndrome.
12 Closely
related to this goal is the need to understand the con-
comitant dimensions of the condition.Among the more
important of these are its underlying biological sub-
strates, since they are likely to represent the effects of
schizophrenia genes more closely than are clinical symp-
toms. Eventually, the inclusion of biological criteria is
likely to improve the specificity of diagnostic criteria,
both for schizotaxia and for schizophrenia.
In the near future, the study of biological measures can
further an understanding of schizotaxia in at least three
interacting ways. First, it can help define and validate
the syndrome.There is a large body of literature showing
neurobiological abnormalities in schizophrenia,at many
levels of analysis. These range from relatively macro-
scopic changes in brain morphology, such as enlarged
ventricles,to molecular biological abnormalities,such as
reduced transcription of messenger RNAs for various
proteins in circumscribed brain regions. A smaller but
substantial subset of these abnormalities also occurs in
family members and, like negative symptoms and neu-
ropsychological deficits, may provide phenotypes for
schizotaxia. Reductions in ventricular size
61 or in brain
regions, such as the amygdala, hippocampus, and thala-
mus,
62,63 diminished sensory gating of auditory P50
evoked potentials (see, for example, references 64 and
65), lowered levels of plasma homovanillic acid,
66 and
reductions in hippocampal N-acetyl aspartate (NAA)
67
are among a growing list of abnormalities that are cur-
rently generating research.Which,if any,of these abnor-
malities are related to the features of schizotaxia that
were outlined above? One way to validate schizotaxia
will be to determine whether current schizotaxic fea-
tures (ie, negative symptoms and neuropsychological
deficits) are associated with these or other biological
abnormalities.As these associations are made, the bio-
logical abnormalities may come to be incorporated into
the conception of schizotaxia and, presumably, into the
diagnostic criteria for the syndrome.
The second way that biological features can facilitate
the conceptualization of schizotaxia is by helping to dif-
ferentiate features of schizotaxia that are primarily
markers, or consequences, of the disorder from those
that are more important in producing the symptoms of
the disorder.This is certainly a complicated issue at this
stage in our understanding of schizotaxia, and it would
probably be premature to classify any biological abnor-
mality in relatives as etiologically insignificant. How-
ever, some types of abnormalities may be particularly
informative, and more clearly relevant to schizotaxic
symptoms. Among these, for example, are deficits
involving hippocampal circuitry that is involved in
mediating the experience-dependent synaptic plastic-
ity that underlies some forms of learning and memory.
Hippocampal deficits are also significant in schizo-
phrenia because they may contribute to dorsolateral
prefrontal dysfunction,and to psychotic symptoms (see,
for example,references 40,65,and 68).In schizophrenic
patients, these deficits may include smaller cell sizes
and neuropils,and reduced transcription of certain pro-
teins involved in neuronal transmission,such as growth-
associated protein–43 (GAP-43) and subunits of
non–N-methyl-D-aspartate (NMDA) glutamate recep-
tors.
68 These latter deficits involve the “trisynaptic cir-
cuit” of the hippocampus, including the CA3 region of
Ammon’s horn, which is also a locus of impaired sen-
sory gating.
65 The conceptual (eg, its putative roles in
learning and memory, and in filtering out, or gating,
unimportant information from the environment) and
empirical (ie,its demonstrated abnormalities in schizo-
phrenic patients and their relatives) significance of the
hippocampus thus underscores the importance of deter-
mining whether hippocampal-based deficits are associ-
ated with the clinical and neuropsychological symptoms
of schizotaxia we described above. Similar arguments
may be made for other brain regions.
The third and most important reason for studying the
neurobiological etiology of schizotaxia is to provide a
foundation for the rational development of treatment
strategies for schizotaxia, and prevention strategies for
schizophrenia. Our initial treatment of schizotaxia
(described above) involved low doses of risperidone,
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263one of the newer antipsychotic medications,because we
reasoned that it might ameliorate some of the same
problems in schizotaxic relatives that it does in schizo-
phrenic patients.While the reasons for its effectiveness
remain unclear,they probably do not include its antipsy-
chotic properties, since the schizotaxic relatives were
(by definition) not psychotic.As neurobiological mech-
anisms of schizotaxia become elucidated,treatments will
likely include options that are broader and more specific
than antipsychotic treatments alone.Some of these may
be tested in the near future. For example, the demon-
stration that nicotine transiently normalizes impaired
sensory gating in relatives implicates cholinergic neu-
rotransmission in the normal mediation of the “filter-
ing”function.
69 Interestingly,we recently found that glu-
cose, which also facilitates hippocampal cholinergic
function (see, for example, references 70 and 71),
improves long-term verbal memory in schizophrenic
patients treated with clozapine.
72 Whether glucose can
also attenuate cognitive dysfunctions in schizotaxia
remains to be tested,but it does illustrate the possibility
that a broad range of nonanti-psychotic treatments (with
or without concomitant low doses of antipsychotic med-
ications) may be useful in treating schizotaxia.
As the biological bases of schizotaxia become clearer,so
will diagnostic criteria for the syndrome.This will allow
the development of more targeted treatment strategies
and homogeneous samples of research subjects. If suc-
cessful treatments for schizotaxia can be demonstrated
in adults, then the most important goal of schizotaxia
research can be embarked upon,which is the prevention
of schizophrenia.While we are certainly not at that point
yet,we may be cautiously optimistic that the issue now is
more related to when, rather than if, we will achieve
that goal.❑
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Esquizofrenia: vulnerabilidad versus
enfermedad
Uno de los aspectos más importantes en el trata-
miento de la esquizofrenia es el diagnóstico y la
intervención precoces. El objetivo último de la
investigación en esta enfermedad es su preven-
ción. Uno de los impedimentos al desarrollo de
estrategias de prevención, sin embargo, es el
hecho que aun no conocemos cuál es la probabi-
lidad para desarrollar esquizofrenia previo a la
aparición de la psicosis. En consecuencia, los
intentos de tratamiento precoz se focalizan en el
“pródromo”, el cual involucra síntomas precoces
de psicosis. En un artículo complementario, noso-
tros sugerimos recientemente que el trabajo de
prevención no debe centrarse sólo en el pródro-
mo, sino también en la “esquizotaxia”, que es
una condición clínicamente significativa que
puede reflejar la vulnerabilidad a la esquizofre-
nia en ausencia de psicosis. Ya que la esquizota-
xia puede ser evaluada previo al pródromo, los
estudios de esquizotaxia pueden conducir a pro-
gramas de prevención más efectivos. En este artí-
culo nosotros continuamos con la caracterización
de la esquizotaxia al referirnos a las raíces etio-
lógicas de ella, como también a su probable
curso durante el neurodesarrollo, su expresión
clínica y su tratamiento. Finalmente se revisa la
importancia de incluir variables neurobiológicas
en la conceptualización y eventual diagnóstico
de esquizotaxia.
Schizophrénie : vulnérabilité versus
maladie
L’importance d’un diagnostic et d’une prise en
charge précoces du traitement de la schizophré-
nie est actuellement de plus en plus reconnue.
L’objectif ultime d’une telle recherche est la pré-
vention de la maladie. Néanmoins, l’obstacle
majeur au développement de stratégies préven-
tives est que nous ne sommes pas encore
capables de définir la susceptibilité d’un patient
vis-à-vis de la schizophrénie avant la survenue de
la psychose. De ce fait, des tentatives de traite-
ment précoce sont centrées sur les “ prodromes ”,
qui comprennent les symptômes précoces de la
psychose. Dans un article précédent traitant du
même thème nous avons récemment suggéré
que le travail de prévention devait se concentrer
non seulement sur les prodromes mais égale-
ment sur la “ schizotaxie “, qui représente un
état cliniquement significatif qui pourrait reflé-
ter la vulnérabilité vis-à-vis de la schizophrénie en
l’absence de psychose. Puisque la schizotaxie
peut être évaluée avant la survenue des pro-
dromes, les études sur la schizotaxie pourraient
conduire à des programmes de prévention plus
efficaces. Dans cet article nous poursuivons la
caractérisation de la schizotaxie en nous intéres-
sant tout particulièrement à ses bases étiolo-
giques, ainsi qu’à sa probable évolution neuro-
développementale, son expression clinique et
son traitement. Enfin, l’importance de l’inclusion
des variables neurobiologiques dans la concep-
tualisation et le diagnostic éventuel de la schizo-
taxie est passée en revue.Clinical research
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